Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in MDD with Mixed Features (RESOLVE2)
NCT01423240Phase 3Withdrawn
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lurasidone in major depressive disorder (MDD), sponsored by Sumitomo Pharma America. Planned start Jan 2012; status: withdrawn.
02
Drugs
lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01423240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423240.